RegulationBreakthrough Therapy (US), Fast Track (US), Orphan Drug (US), Orphan Drug (EU), Priority Review (CN), Overseas New Drugs Urgently Needed in Clinical Settings (CN)

Gene Sequence

Sequence Code 319372596

Source: *****

Clinical Trials associated with Rilonacept

NCT03737110 / CompletedPhase 3

Phase 3, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study With Open-label Extension, to Assess the Efficacy and Safety of Rilonacept Treatment in Subjects With Recurrent Pericarditis

The primary objective of this study was to assess the efficacy of rilonacept treatment in participants with recurrent pericarditis.

Start Date07 Jan 2019

Sponsor / Collaborator

Kiniksa Pharmaceuticals (UK) Ltd.

NCT03980522 / CompletedPhase 2

An Open-Label Pilot Study of KPL-914 in Recurrent Pericarditis

The purpose of this study is to assess the preliminary efficacy and safety of KPL-914 treatment in participants with recurrent pericarditis.

Start Date24 Jan 2018

Sponsor / Collaborator

Kiniksa Pharmaceuticals (UK) Ltd.

NCT02828033 / Unknown statusEarly Phase 1

A Pilot Trial of Rilonacept for Treatment of Autoimmune Neurosensory Hearing Loss

This study is an open label proof of concept study of rilonacept for patients with ANSHL

Start Date01 Feb 2017

Sponsor / Collaborator

Metroplex Clinical Research Center

[+1]

100 Clinical Results associated with Rilonacept

100 Translational Medicine associated with Rilonacept

100 Patents (Medical) associated with Rilonacept

410

Literatures (Medical) associated with Rilonacept

01 Feb 2024·International immunopharmacology

Colchicine-intolerant familial mediterranean fever patients: A comparative study between different colchicine doses and IL-1 inhibitor monotherapy

Article

Author: Karadeniz, Hazan ; Kaya, Burcugul ; Gun, Mert ; Goker, Berna ; Kucuk, Hamit ; Kardas, Riza Can ; Vasi, Ibrahim ; Avanoglu Guler, Aslihan ; Yildirim, Derya ; Erden, Abdulsamet ; Duran, Rahime ; Tufan, Abdurrahman ; Ozturk, Mehmet Akif

OBJECTIVE:

Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease. Colchicine is the primary treatment for FMF, although some patients do not respond well or are unable to tolerate it. For these patients, the addition of interleukin-1 (IL-1) antagonists is the preferred option. However, the impact of colchicine treatment alongside the use of IL-1 antagonists remains unclear.

METHODS:

We recruited adult FMF patients who satisfied the Eurofever and Pediatric Rheumatology International Trials Organization classification criteria and were receiving IL-1 antagonist treatment from our FMF cohort. All the patients exhibited colchicine intolerance or resistance. As per the FMF cohort protocol, the patients were longitudinally followed up, including assessments of their C-reactive protein, erythrocyte sedimentation rate, autoinflammatory disease activity index (AIDAI), and autoinflammatory damage index (ADDI).

RESULTS:

Among the 125 patients (68 female and 57 male), 96 received a combination of IL-1 antagonists and the maximum tolerated dose of colchicine, whereas 29 were treated exclusively with IL-1 antagonists due to colchicine intolerance. The patients' inflammatory markers, AIDAI activity, and ADDI damage scores did not differ significantly between the two groups during the follow-up period. Notably, the drug retention rates were significantly higher in the patients treated solely with IL-1 antagonists.

CONCLUSION:

While the typical approach is to maintain colchicine treatment alongside the use of IL-1 antagonists, for patients who cannot tolerate effective colchicine doses, IL-1 antagonists alone may effectively control FMF disease activity.

01 Jan 2024·Heart (British Cardiac Society)

Correction:Transition to rilonacept monotherapy from oral therapies in patients with recurrent pericarditis

Article

01 Dec 2023·Autoimmunity reviews

Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission

Review

Author: Cantatore, Francesco Paolo ; Favalli, Ennio ; Gattamelata, Angelica ; Tomelleri, Alessandro ; Baldini, Chiara ; Pappagallo, Giovanni ; Faggioli, Paola ; Belfiore, Norma ; Chimenti, Maria Sole ; Montecucco, Carlomaurizio ; Giacomelli, Roberto ; Sebastiani, Gian Domenico ; Cantarini, Luca ; Cavalli, Giulio ; Sulli, Alberto ; Sfriso, Paolo ; Ruscitti, Piero ; Marotto, Daniela ; Piga, Matteo ; Quartuccio, Luca ; Bindoli, Sara ; Parisi, Simone ; Colafrancesco, Serena ; Leccese, Pietro ; Caporali, Roberto ; Iacono, Daniela ; Grava, Chiara ; Picchianti-Diamanti, Andrea ; Ursini, Francesco ; Vitetta, Rosetta ; Emmi, Giacomo ; Paroli, Marino ; Sota, Jurgen ; Colaci, Michele ; Manara, Maria ; Caso, Francesco ; Berti, Alvise ; Iannone, Florenzo ; Pantano, Ilenia ; Frassi, Micol ; Bartoloni, Elena ; Gabini, Marco ; Lopalco, Giuseppe ; Guggino, Giuliana ; Tirri, Enrico ; Bernardi, Cristina ; Monaco, Andrea Lo ; Campochiaro, Corrado ; Priori, Roberta ; Pistone, Giovanni ; Italiano, Giovanni ; Gremese, Elisa ; Padula, Angela ; De Stefano, Ludovico ; De Angelis, Rossella ; Foti, Rosario ; Vitale, Antonio ; Dagna, Lorenzo ; Brucato, Antonio ; Govoni, Marcello ; Bettio, Silvano ; Ciccia, Francesco

We performed a comprehensive systematic targeted literature review and used the Delphi method to formulate expert consensus statements to guide the treatment of adult-onset Still's disease (AOSD) to achieve an early and long-term remission. Seven candidate statements were generated and reached consensus in the first round of voting by the panel of experts. We postulate: (i) In patients with AOSD with predominant arthritis at onset who achieved no disease control with glucocorticoids (GCs), the use of methotrexate can be considered, whereas the use of cyclosporin A and low-dose GCs should not (Statements 1-3); (ii) In patients with AOSD with poor prognostic factors at diagnosis, an IL-1 inhibitor (IL-1i) in addition to GCs should be taken into consideration as early as possible (Statement 4); (iii) A switch to an IL-6 inhibitor (IL-6i) may be considered in patients with AOSD with prevalent joint involvement, who are unresponsive or intolerant to IL-1i (Statement 5); (iv) Drug tapering or discontinuation may be considered in patients who achieved a sustained clinical and laboratory remission with IL-1i (Statement 6); (v) In patients with AOSD who failed to attain a good clinical response with an IL-1i, switching to an IL-6i may be considered in alternative to a different IL-1i. TNF-inhibitors may be considered as a further choice in patients with a prominent joint involvement (Statement 7). These statements will help clinicians in treatment decision making in patients with AOSD.

News (Medical) associated with Rilonacept

24 Jun 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis

– Campaign to elevate experiences from the recurrent pericarditis community and provide resources to patients and caregivers – HAMILTON, Bermuda, June 24, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced a partnership with National Hockey League (NHL) Hall-of-Famer, Henrik Lundqvist, to raise awareness in support of patients suffering from recurrent pericarditis. Lundqvist has faced the challenges of living with this painful and debilitating chronic autoinflammatory cardiovascular disease. The campaign will kick off in September of this year. Pericarditis is marked by a profound inflammation of the pericardial tissue in the multi-layered sac that surrounds the heart. The associated sharp chest pain frequently requires urgent care and hospitalization, and patients often believe they are having a heart attack. Patients experiencing recurrent pericarditis flares suffer wide-ranging effects on quality of life, physical activity, and overall well-being. “Despite the significant impact of recurrent pericarditis on patients’ lives, the limited understanding of the disease often results in delayed diagnosis and treatment,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are honored to collaborate with Henrik Lundqvist to raise awareness of the realities of suffering from recurrent pericarditis. We believe this collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares.” For more information on recurrent pericarditis, visit whatispericarditis.com. To learn about the first and only U.S. Food and Drug Administration-approved therapy for recurrent pericarditis, visit arcalyst.com. About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data show that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection).While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection.Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST.Medicines that affect the immune system may increase the risk of getting cancer.Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction.Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides.Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the timing of the campaign, our belief that our collaboration will help educate and inspire individuals to take proactive steps to access appropriate medical care early on to prevent future flares and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

Vaccine

17 Jun 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative

– Initiative aimed at improving access and outcomes for patients with recurrent pericarditis – – American Heart Association to work with champions at 15 healthcare sites to implement initiative activities and improve care quality – HAMILTON, Bermuda, June 17, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today announced its sponsorship of the American Heart Association’s new Addressing Recurrent Pericarditis initiative, a multi-faceted effort to improve quality of care through identification, dissemination, and implementation of best practices for the diagnosis and management of recurrent pericarditis. “We are proud to sponsor the American Heart Association’s Addressing Recurrent Pericarditis initiative. Recurrent pericarditis is a rare, chronic, flaring disease, in which patients are frequently misdiagnosed or undertreated due to a lack of access to expert care. In addition to elevating awareness and knowledge around recurrent pericarditis, this initiative will also help strengthen overall care by working to improve processes for diagnosing, referring, and treating patients,” said John F. Paolini, M.D., Ph.D., FACC, Chief Medical Officer of Kiniksa. “Furthermore, this initiative will facilitate knowledge-sharing across a collaborative network of healthcare providers, with the objective of establishing a clear model to streamline patient access to expert care and improved outcomes nationwide.” Through the Addressing Recurrent Pericarditis initiative, the American Heart Association will establish a learning collaborative of champions at fifteen healthcare sites for recurrent pericarditis care. These champions will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions. The ultimate goal of the initiative is to improve outcomes and quality of life for recurrent pericarditis patients by disseminating best practices through national education, model sharing, abstract development, and patient- and physician-targeted podcasts and webinars. “Recurrent pericarditis symptoms can have significant impact on emotional health and quality of life, but they often go undiagnosed and untreated,” said Mariell Jessup, M.D., FAHA, Chief Science and Medical Officer of the American Heart Association. “This new initiative will share insights and best practices nationally to improve identification and treatment for patients with this disease.” Participating sites in the learning collaborative include: Ascension St. Thomas Heart (Nashville, Tennessee)Bluhm Cardiovascular Institute, Northwestern Medicine (Chicago, Illinois)Brigham & Women’s Hospital (Boston, Massachusetts)Cleveland Clinic (Cleveland, Ohio)Houston Medical Hospital (Houston, Texas)Knight Cardiovascular Institute Cardiology Clinic, Oregon Health & Science University (Portland, Oregon)Massachusetts General Hospital (Boston, Massachusetts)Mayo Clinic – Rochester (Rochester, Minnesota)My Cardiologist/CVAUSA (Miami, Florida)New York University Grossman School of Medicine (New York, New York)Pacific Heart Institute (Santa Monica, California)The Regents of the University of California Irvine (Irvine, California)University of Michigan (Ann Arbor, Michigan)University of Utah Hospital (Salt Lake City, Utah)University of Virginia (Charlottesville, Virginia) About Recurrent PericarditisRecurrent pericarditis is a painful and debilitating chronic autoinflammatory cardiovascular disease marked by inflammation of the pericardium and is often associated with changes in electrical conduction and sometimes buildup of fluid around the heart, called pericardial effusion. Recurrent pericarditis symptoms have an impact on quality of life, limit physical activities, and lead to frequent emergency department visits and hospitalizations. Data shows that approximately 40,000 patients in the U.S. seek and receive treatment for recurrent pericarditis each year. Of that group, approximately 14,000 patients experience two or more recurrences due to persistent underlying disease or inadequate response to conventional therapies, such as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and corticosteroids. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. Forward-Looking StatementsThis press release contains forward-looking statements. In some cases, you can identify forward- looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: the ultimate number of healthcare sites that will participate in the learning collaborative; our belief that the Addressing Recurrent Pericarditis initiative will (a) improve quality of care through identification, dissemination and implementation of best practices for the diagnosis and management of recurrent pericarditis, (b) elevate awareness and knowledge around recurrent pericarditis, (c) strengthen overall care by working to improve processes for diagnosing, referring and treating patients, and (d) facilitate knowledge-sharing across a collaborative network of healthcare providers to streamline patient access to expert care and improve outcomes nationwide; that the healthcare champions participating in the Addressing Recurrent Pericarditis initiative will analyze patient identification and referral pathways, seeking to identify gaps and pragmatic solutions with the ultimate goal of improving outcomes, quality of life, identification and treatment for recurrent pericarditis patients by disseminating insights and best practices; and our belief that all of our product candidates offer the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our and our partners’ achievements to be materially different from those expressed or implied by the forward-looking statements. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Every Second Counts! ® Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

AHA

07 May 2024

·www.globenewswire.com

Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference

HAMILTON, Bermuda, May 07, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on Tuesday, May 14, 2024 at 10:40 a.m. Pacific Time (1:40 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About KiniksaKiniksa is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s immune-modulating assets, ARCALYST®, abiprubart, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. For more information, please visit www.kiniksa.com. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ®Kiniksa Investor and Media ContactRachel Frank(339) 970-9437rfrank@kiniksa.com

100 Deals associated with Rilonacept

External Link

KEGG	Wiki	ATC	Drug Bank
D06635	Rilonacept	L04AC04	DB06372

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pericarditis	US	Kiniksa Pharmaceuticals (UK) Ltd.	18 Mar 2021
Deficiency of Interleukin-1 Receptor Antagonist	US	Kiniksa Pharmaceuticals (UK) Ltd.	18 Dec 2020
Familial cold urticaria	US	Kiniksa Pharmaceuticals (UK) Ltd.	18 Dec 2020
Cryopyrin-Associated Periodic Syndromes	US	Kiniksa Pharmaceuticals (UK) Ltd.	27 Feb 2008
Familial Cold Autoinflammatory Syndrome 2	US	Kiniksa Pharmaceuticals (UK) Ltd.	27 Feb 2008

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gout	Phase 3	DE	Regeneron Pharmaceuticals, Inc.	01 Jul 2009
Gout	Phase 3	IN	Regeneron Pharmaceuticals, Inc.	01 Jul 2009
Gout	Phase 3	ID	Regeneron Pharmaceuticals, Inc.	01 Jul 2009
Gout	Phase 3	ZA	Regeneron Pharmaceuticals, Inc.	01 Jul 2009
Gout	Phase 3	TW	Regeneron Pharmaceuticals, Inc.	01 Jul 2009
Primary gout	Phase 3	US	Regeneron Pharmaceuticals, Inc.	01 Mar 2009
Arthritis, Gouty	Phase 3	US	Regeneron Pharmaceuticals, Inc.	01 Feb 2009
Arthritis, Gouty	Phase 3	CA	Regeneron Pharmaceuticals, Inc.	01 Feb 2009
Scleroderma, Diffuse	Phase 2	US	Regeneron Pharmaceuticals, Inc.	01 Dec 2011
Atherosclerosis	Phase 2	US	National Heart, Lung & Blood Institute	01 Dec 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03737110 (RHAPSODY, Pubmed)	Phase 3	Pericarditis	-	Rilonacept	zudszapooc(zxfutdyemh) = lcmtfritua gvkfwsraoo (xndecpcbhn )	-	19 Mar 2024
RHAPSODY (ACR2021)	Phase 3	Pericarditis C-reactive protein (CRP)	86	Rilonacept 320 mg SC load, 160 mg SC weekly	mlnivaeuie(zdczzqvixd) = qoiqetfqvc ksvhujlcjm (rrxtbzpkmi )	Positive	08 Nov 2021
				Placebo	mlnivaeuie(zdczzqvixd) = hrjabnkgye ksvhujlcjm (rrxtbzpkmi )
NCT03980522 (CTgov)	Phase 2	Pericarditis	26	KPL-914 (KPL-914: Part 1 Participants)	bpnkjzfnar(wzojpevmqg) = tlrvqejjkv pfailasgxq (jmxwdgjmzj, xvnrfzowdv - ehxibbjkxg) View more	-	27 May 2021
				KPL-914 (KPL-914: Part 2 Participants)	bpnkjzfnar(wzojpevmqg) = uqpqofwlgy pfailasgxq (jmxwdgjmzj, ufbpqjrfhq - gqflnpmxon) View more
NCT03980522 (Pubmed \| Heart) Manual	Phase 2	Idiopathic Recurrent Pericarditis	25	rilonacept	agqoyahwkv(wexvgvihlk) = from 4.62 mg/dL at baseline to 0.38 mg/dL fjncalxeoc (hbavusauba ) View more	Positive	23 Nov 2020
NCT01538719 (CTgov)	Phase 1/2	Scleroderma, Diffuse	24	Placebo (Placebo)	bduhhinaqw(iealnfedql) = vmzolwqmce rrjcahjlii (hpmfkzyuoq, ykowrwzggv - vabwzmaxop) View more	-	01 May 2018
				Rilonacept (Rilonacept)	bduhhinaqw(iealnfedql) = ueeajkctrz rrjcahjlii (hpmfkzyuoq, yztpmosbsz - lodxacaoke) View more
NCT01801449 (CTgov)	Phase 2	Deficiency of Interleukin-1 Receptor Antagonist	6	Rilonacept	zmgvfgydbc(daflfdvjhc) = idywamjskg akvenfhtzj (katqfgglyz, bdtzlzxvuu - cpqsgowixz) View more	-	16 Oct 2017
NCT01459796 (CTgov)	Phase 3	Gout	220	Placebo+Allopurinol (Placebo)	jzfqaupmrl(giuvdihngo) = iweoqfewyj nyignhoyak (jgufwlaijo, adjyjrmzve - wxhaygertu) View more	-	18 Jul 2017
				Allopurinol+Rilonacept (Rilonacept 80 mg)	jzfqaupmrl(giuvdihngo) = lswvlbtutd nyignhoyak (jgufwlaijo, zzxmvdvjab - aymhaiyote) View more
NCT00610363 (CTgov)	Phase 2	Gout	83	Placebo (for Rilonacept) (Placebo)	jpmzkdbpvi(nvmmdcbubm) = pqoeutacws xqqoqzgaky (voyoagtkbt, sfiypedmex - kkamwkupnr) View more	-	02 May 2017
				Rilonacept (Rilonacept 160 mg)	jpmzkdbpvi(nvmmdcbubm) = neswebttvp xqqoqzgaky (voyoagtkbt, poxotsowsv - iihkjzgywc) View more
NCT00855920 (CTgov)	Phase 3	Primary gout	225	Placebo (for Rilonacept)+Indomethacin (Placebo (for Rilonacept) and Indomethacin)	ojdmvjvgue(rhjikqrxdo) = qgaaqxmmbt mhsbexgelj (gfzvftltax, gooofjmbno - ntwnbhngkx) View more	-	28 Apr 2017
				Indomethacin+Rilonacept (Rilonacept and Indomethacin)	ojdmvjvgue(rhjikqrxdo) = ciukawmzub mhsbexgelj (gfzvftltax, xakpvleudr - qblpovurxb) View more
NCT00829829 (CTgov)	Phase 3	Arthritis, Gouty	241	Placebo (Placebo)	zxpdflnimb(ttzqoqftze) = mtnutoheco trtzfxlkdw (oxkmifntbs, ehiwinocbq - pvuclswbtc) View more	-	28 Apr 2017
				Rilonacept 80 mg (Rilonacept 80 mg)	zxpdflnimb(ttzqoqftze) = insxjhtfto trtzfxlkdw (oxkmifntbs, ezkgrwsgcc - mvdvgntemg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis